MICROTECH MED-B (02235): The continuous glucose monitoring system AiDEX G9 has received registration approval from the National Medical Products Administration.

MICROTECH MED-B (02235) has announced that its next-generation split-type continuous glucose monitoring system, AiDEX G9, has recently received market approval from the National Medical Products Administration. Compared to the first-generation split-type product, AiDEX G9 represents a technological innovation and transformation. It has undergone comprehensive upgrades in size, portability, and wearing comfort, providing diabetes patients with a lighter and more comfortable experience in blood glucose management. China is one of the largest diabetes markets in the world. According to the International Diabetes Federation (IDF) "Global Diabetes Map 2025," there will be approximately 148 million adults aged 20 to 79 with diabetes in China by 2024, ranking first globally. Additionally, there are 274 million people with prediabetes in China, forming a significant potential high-risk population for diabetes. The approval of this product will further enrich the group's product pipeline, achieve broader user coverage, and help the group seize development opportunities in the Chinese market, consolidating and enhancing the group's market position and competitive advantage in the continuous glucose monitoring field. In the future, the company will continue to focus on the global development of diabetes monitoring, treatment, and management methods, continuously promoting technology and product innovation in related fields.